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The renin-angiotensin system (RAS) is a hormone system that has been classically known as a blood pressure regulator but is
becoming well recognized as a proinﬂammatory mediator. In many diverse tissues, RAS pathway elements are also produced
intrinsically, making it possible for tissues to respond more dynamically to systemic or local cues. While RAS is important for
controlling normal inﬂammatory responses, hyperactivation of the pathway can cause neural dysfunction by inducing accelerated
degradationofsomeneuronalproteinssuchassynaptophysinandbyactivatingpathologicalglialresponses.Chronicinﬂammation
and oxidative stress are risk factors for high incidence vision-threatening diseases such as diabetic retinopathy (DR), age-related
macular degeneration (AMD), and glaucoma. In fact, increasing evidence suggests that RAS inhibition may actually prevent
progression of various ocular diseases including uveitis, DR, AMD, and glaucoma. Therefore, RAS inhibition may be a promising
therapeutic approach to ﬁne-tune inﬂammatory responses and to prevent or treat certain ocular and neurodegenerative diseases.
1.Introduction
Most visual disorders occur in the retina, which is a part of
the central nervous system (CNS) and consists of neurons,
glia,pigmentepithelium(RPE),andbloodvessels.Currently,
diabetic retinopathy (DR), age-related macular degeneration
(AMD), and glaucoma are the top causes of blindness in the
developed countries. These diseases can occur when local
or systemic neuronal and vascular homeostasis mechanisms
are dysregulated. The highest risk factor for many of these
diseases is aging [1–3], and as is the case with other age-rel-
ated diseases such as Alzheimer’s disease, cardiovascular dis-
ease, cancer, arthritis, osteoporosis, and hypertension, accu-
mulating evidence suggests that chronic inﬂammation and
oxidativestresscanaccelerateorpromotediseaseprogression
[4–6].
The renin-angiotensin system (RAS) is classically known
as a systemic blood-pressure-regulating system. However, it
is becoming widely recognized as an inﬂammation regulator
as well. Independent of systemic RAS, tissue intrinsic RASs
have been identiﬁed in various tissues (including the retina)
and are important for maintaining local homeostasis. Ele-
ments of the RAS pathway are highly conserved in many
species including invertebrates and humans demonstrating
that its functions are evolutionarily conserved, although spa-
tial expression patterns diﬀer slightly between diﬀerent spec-
ies [7].
We have reported that angiotensin II type 1 receptor
blocker (ARB) suppresses retinal neural dysfunction in ani-
mal models of acute inﬂammation [8] or diabetes [9]. Other
groups and our own have also reported that ARBs can pro-
tect retinal vascular inﬂammation [10–19] and neuronal2 International Journal of Inﬂammation
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apoptosis [20–23]. Furthermore, it was recently reported by
two independent groups that daily oral administration of
ARB may prevent the progression of diabetic retinopathy in
randomized multicenter clinical trials [24–26]. In this paper
we will summarize these ﬁndings and other studies demon-
strating that RAS modulation may prevent ocular patho-
genesis. We will also outline the similarities and diﬀerences
between retinal and brain RAS. Lastly, we will describe the
potential mechanisms through which RAS inhibition may
preserve neuronal function and viability while combating
ocular diseases.
2.R ASasanI nﬂ am m at o ryCasc ad e
Renin was discovered as a hypertensive agent in rabbit kid-
neys in 1898. It was later found to induce the release of a va-
soconstrictive agent in experimental models of hypertension
induced by renal ischemia [27]. Two independent groups
identiﬁed the end product of this hypertensive cascade in
1939andnamedit“hypertension”[28]or“angiotonin”[29].
It has since been renamed “angiotensin” [30]. The RAS
pathway as we know it today began to take shape once
angiotensin-convertingenzyme(ACE)wasidentiﬁedin1956
[31]. We now know that once renin is proteolytically proc-
essed from its precursor prorenin by proteases and released
from the kidney, it converts angiotensinogen to angiotensin
I in the liver. Angiotensin I is ﬁnally converted to angiotensin
II by ACE which is predominantly expressed in vascular en-
dothelial cells (ECs) and is located in highly vascularized tis-
suessuchasthelung(Figure 1).AngiotensinIIstimulatesva-
scularsmoothmusclecells(VSMCs)thatlineendothelialcel-
ls to contract and induce vasoconstriction.
There are two primary receptors for angiotensin II: an-
giotensin II type 1 receptor (AT1R) and AT2R; AT1R ap-
pears to exert predominant functions in blood vessels. Ge-
nerally, AT1R signaling normally induces vasoconstriction
while AT2R signaling induces vasodilation. However, the
rolesofAT1RandAT2Rinpathophysiologicalconditionsare
currently under debate [32–34]. AT1R is a seven-transmem-
brane G protein-coupled receptor [35, 36]. Once stimulated
in VSMCs G proteins activate phospholipase C (PLC) and
inositol-1,4,5-triphosphate (IP3) to open calcium channels
in the endoplasmic reticulum [37]. As a result, increase ofInternational Journal of Inﬂammation 3
cytosolic calcium induces phosphorylation of myosin light
chain, VSMC contraction, and vasoconstriction [38, 39].
Independent of systemically circulating angiotensin II
(circulating RAS), most RAS components, including ACE,
were also found to be locally expressed in many tissues [40].
This observation resulted in the hypothesis that in addition
to being converted in particular organs for systemic circu-
lation, angiotensin II could also be synthesized in peripheral
tissues(tissueRAS)whereitwouldexertitseﬀectlocally.Tis-
sueRASelementswereidentiﬁedinvariousorgansincluding
heart [41], kidney [42], adrenal gland [43], brain [44], and
retina (see details below). An important molecule involved
with tissue RAS is (pro)renin receptor which interacts with
prorenintoexertenzymaticactivityofreninwithoutthecon-
ventional proteolysis of the prorenin prosegment [45, 46].
(Pro)renin receptor can be detected in major organs but not
incirculationindicatingthatthismoleculemayplayacritical
roleintheactivationoftissueRAS[46].ThustissueRASmay
be important for ﬁne-tuning global RAS activity or for act-
ing intrinsically to respond to localized insults. However,
(pro)renin receptor may also function independent of renin
activation as a member of the Wnt receptor complex to re-
gulate Wnt/ß-catenin pathway activity [47].
Inadditiontoitscriticalphysiologicalfunctions,RASdy-
sregulation can lead to pathogenesis. In various cardiovascu-
larcell-typeRASshyperactivationcaninducepathogeniccell
migration, hypertrophy, ﬁbrosis, disrupt cell adhesion and
ectopic extracellular matrix (ECM) deposition. AT1R signal-
ing directly activates key signaling pathways for cell growth
and hypertrophy including JAK/STAT (janus kinase/signal
transducer and activator of transcription) [48, 49], ERK
(extracellular-signal-regulated kinase) 1/2 [50–52], and p38
MAPK (mitogen-activated protein kinase) [53]. Indeed, an-
giotensin II/AT1R signaling can potentiate oxidative stresses
and inﬂammatory responses by activation of NAD(P)H (ni-
cotinamide adenine dinucleotide phosphate) oxidases [54–
57]. Angiotensin II can also activate EGFR (epidermal grow-
th factor receptors) and induces ﬁbronectin synthesis and
TGFβ (transforming growth factor beta) activity to promote
ﬁbrosis and ECM formation [58, 59]. AT1R signaling can
activate NFκB (nuclear factor kappa-light-chain-enhancer of
activatedBcells)[60–62]andAP-1(activatorprotein1)toin-
itiate transcription of multiple proinﬂammatory genes [61,
63, 64]. AT1R also induces accumulation, adhesion, and in-
ﬁltration of inﬂammatory cells via activation of PAI-1 (plas-
minogen activator inhibitor-1) [65] and MCP-1 (monocyte
chemotactic protein-1) [62] to promote atherosclerosis [66].
Taken together, these ﬁndings provide strong evidence that
RAS is not just a regulator of blood pressure, but also re-
gulates an inﬂammatory cascade.
The eﬀects of circulating and tissue RAS can be control-
led with RAS inhibitors. After the ﬁrst ACE inhibitor (ACEI)
was developed [67], many other RAS inhibitors including
ARB [68, 69] have been established and approved for com-
mercial use as hypertension drugs (Figure 1). RAS inhibition
not only prevents hypertension but also protects tissues aga-
inst injury by limiting the potency of deleterious inﬂamma-
tory responses. Since aging is considered to be, in part, the
result of chronic inﬂammation [70], it may not be too
surprising that the use of RAS inhibitors or genetic deletion
of AT1R has potential to extend the life span in hypertensive
[71–73]o rn o r m o t e n s i v e[ 74] mammals.
3.Brainandthe RetinalRAS
In addition to regulating vasoconstriction, another impor-
tant physiological function of RAS is osmoregulation in the
CNS (e.g., water and sodium intake, sympathetic activity,
and release of vasopressin) [75–77]. AT1R is expressed in
brain neurons and mediates osmoregulation [76]b ys t i m u -
latingthereleaseofvasopressininthepituitaryglandandsig-
naling the kidney to conserve water [76]. Furthermore ang-
iotensin II/AT1R signaling in the brain forces individuals to
stimulate increased thirst and consume more drinking water
[77].SinceangiotensinIIhasahighmolecularweight,itdoes
not cross the blood-brain barrier (BBB) [78]. Therefore in-
trinsic RAS networks must be responsible for inducing the
dipsogenic activity. Additionally, every component of the
RAS pathway including angiotensinogen, ACE, and ang-
iotensin II receptors is expressed in the brain [75, 76, 79–81].
BrainRAScanalsobecomedysregulated;thishasbeenshown
to induce oxidative stress and inﬂammation [82]. However,
RAS inhibitors have neuroprotective eﬀects in brain inﬂam-
mationandischemiawithoutinducingantihypertension(see
detail below).
The retina also has an intrinsic tissue RAS. In the eye,
prorenin protein and renin activity can be detected in the
vitreousﬂuid[83–85]andproreninmRNAhasbeendetected
in Muller glia [86] and in the ciliary body (CB) cells [87].
(Pro)renin receptor is expressed in ECs, Muller glia, and
retinal ganglion cells (RGCs) [88, 89]. Angiotensinogen is
found in CB [90], Muller glia [91], and RPE [92]. ACE is
synthesized in the neural retina [93, 94]a n dc a nb ed e t e c -
t e di nR G C s ,p h o t o r e c e p t o r s[ 95], and Muller glia [96]. An-
giotensin II, the ﬁnal product of RAS, can be detected in the
vitreousﬂuid[97]andintheneuralretina[98].Interestingly,
the normal concentration of angiotensin II in ocular ﬂuid is
higherthaninplasma[97],conﬁrmingtheexistenceoftissue
RAS in the eye.
Intheretina,angiotensinIIreceptorsaredetectedbothin
ECs and in neuronal cells, which are located outside and in-
sideoftheblood-retina barrier(BRB),respectively[8,92,99,
100]. AT1R is found in the presynaptic terminals of photo-
receptors and of interneurons in the retina [8]a sw e l la si n
neurons of the brain [101, 102]( Figure 2). AT1R is also ex-
pressed in RGCs [103], although the physiological function
ofAT1Rintheneuralretinaisnotfullyunderstood.Systemic
administration of ACEI negatively inﬂuences cat and human
neural functions measured by electroretinograms (ERG)
in both systemic blood-pressure-dependent [104] and -in-
dependent manners [105, 106]. Additionally, angiotensin II
increases voltage-dependent calcium currents in cultured
RGCs [103]. Therefore ocular RAS may act as a physiological
neuromodulator.
AT2R is also expressed in the retina [8] but much less is
known how it functions in the eye. Polymorphisms in the
AT2R gene may be linked to glaucoma [107] or diameter of
the retinal arterioles [108].4 International Journal of Inﬂammation
Figure 2: AT1R expression in a neuronal cell line. Immunohisto-
chemistry for angiotensin II type 1 receptor (AT1R) in PC12D cells.
Note that AT1R is detected in presynaptic terminal (arrow) or soma
(arrow head). Scale bar: 20μm.
4. RASand Ocular Diseases
4.1. Uveitis. Increasing evidence suggests that RAS activity
and inﬂammation may be associated with various ocular dis-
eases, and, therefore, RAS inhibitors may be eﬀective thera-
peutic agents. Several lines of evidences suggest that RAS in-
hibitionisaneﬀectivetreatmentforuveitis[8,12,17,18,88].
Endotoxin-induced uveitis (EIU) is induced with intraperi-
toneal injections of lipopolysaccharide (LPS); this results in
upregulated expression of proinﬂammatory and adhesion
molecules such as ICAM-1 (intercellular adhesion molecule
1), MCP-1, IL-6 (interleukin 6), and IFN-γ (interferon-
gamma)[17,88].Thesemoleculesarealsoupregulatedinex-
perimental autoimmune uveoretinitis (EAU) models gener-
ated by immunizing animals with interphotoreceptor retin-
oid-binding protein (IRBP) [18]. The upregulation of these
molecules,however,canbeinhibitedwithARBor(pro)renin
receptor blocker (PRRB). (PRRB is an experimental decoy
peptidethatcontains“handle”regionsequenceof(pro)renin
receptor.) RAS inhibition also suppresses retinal leukocyte
stasis,CD4+ T-cellactivation[17,18,88]. Furthermore, RAS
inhibition suppresses gliosis by preventing STAT3 activation
[8]. Lastly, when the expression levels of RAS pathway com-
ponents are examined in EIU, prorenin, (pro)renin receptor
[88], angiotensin II [8] ,a n dA T 1 R[ 17] levels are elevated
in the retina. These ﬁndings suggest that heightened inﬂam-
matory responses in the eye and RAS activation are strongly
correlated.
4.2. Chronic Inﬂammation and Eye Diseases. Besides being
correlated with classically acute inﬂammation cases such as
uveitis,oneofthelargestriskfactorsfordevelopingprevalent
andvision-threateningdiseasessuchasDR,AMD,andglauc-
oma is aging [1–3] .T h e s ea g e - r e l a t e de y ed i s e a s e s[ 109, 110]
and others [5, 6] are now known to be caused (at least part-
ially) by chronic inﬂammation and oxidative stress. Since
RAS inhibition may prolong the life spans of hypertensive
[71–73]ornormotensive[74]mammals,itislogicalthatage-
related eye diseases may be prevented or treated by suppres-
sing inﬂammation and oxidative stress. The main patho-
logicaleventofDRandAMDisabnormalneovascularization
and VEGF (vascular endothelial growth factor) has been
known to be a large contri-butor for them [111–113]. VEGF
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Figure 3: Downstream of AT1R in vascular inﬂammation and neu-
ral dysfunction. NFκB: nuclear factor kappa-light-chain-enhancer
of activated B cells, AP-1: activator protein 1, UPS: ubiquitin-pro-
teasome system, STAT3: signal transducer and activator of tran-
scription 3, ICAM-1: intercellular adhesion molecule 1, MCP-1:
monocyte chemotactic protein 1, VEGF: vascular endothelial
growth factor, Syp: synaptophysin, Rho: rhodopsin, GFAP: glial ﬁ-
brillary acidic protein.
is a potent angiogenic factor and an inﬂammatory cytokine
that induces the accumulation, adhesion, and inﬁltration of
leukocytes [114, 115]. Inﬂammatory response in the retina
can promote tissue ischemia by inducing vascular regression
(vaso-obliteration) and also pathological angiogenesis [116].
Angiotensin II can induce upregulation of VEGF receptor
(VEGFR)-2 and angiopoietin-2 in retinal ECs [117, 118]a n d
VEGF in retinal pericytes [119]( Figure 3). Oxygen-induced
retinopathy (OIR) is an animal model induced by continual
aeration with 75–80% oxygen in early postnatal stages. OIR
animals develop stereotypical phenotypes and is useful to
evaluatevaso-obliterationandpathologicalangiogenesis(tu-
ft formation) in the developing retina [120] which is largely
re-gulated by VEGF [121]. This phenotype can be preven-
ted with RAS inhibitors ACEI [122, 123], ARB [15], or
PRRB [89, 124] that prevent pathological angiogenesis in
OIR.TheuseofARBandPRRBhastheaddedbeneﬁtofsup-
pressing abnormal angiogenesis without suppressing physio-
logicalvascularregeneration[15,124].Inanimalsexposedto
OIR RAS inhibitors may function to prevent gene expression
of proinﬂammatory molecules and prevent leukocyte inﬁl-
tration. Inﬁltration of VEGF-expressing inﬂammatory cells
into the vitreous cavity is thought to induce pathological an-
giogenesis by causing ECs to grow in the wrong direction
[115].
4.3.DiabeticRetinopathy(DR). DRisoneoftheleadingcaus-
es of blindness in the world [3]. It is characterized by vas-
cularlossduetohyperglycemiaandinﬂammationduetooxi-
dativestressandAGEs(advancedglycationendproducts)ac-
cumulation. In severe cases hypoxia induces abnormal
neovascularization (proliferative diabetic retinopathy, PDR)
in addition to hyperpermeability (diabetic macular edema;
DME).Prorenin[83]andangiot ensinII[125,126]ar efoundInternational Journal of Inﬂammation 5
to be increased in the vitreous humor of PDR and DR pa-
tients. RAS may potentiate the vascular phenotype of DR
by upregulating VEGF/VEGFR-2 signaling (through angio-
tensin II) [118, 119] thereby inducing neovascularization
and promoting blood vessel permeability. In fact, VEGF was
initially named “vascular permeability factor” (VPF) [127].
Multiple attempts have been made to treat DR with RAS
inhibitors. Although in one study ACEI administration se-
emed to attenuate retinal hyperpermeability in diabetic pa-
tients [128], interpretations of these studies are still being ac-
tively debated [129, 130]. However, recently three independ-
ent groups showed that ARB prevents BRB breakdown in
animal models [131–133]. In 1998 and 2008, the results of
randomized double-blind placebo-controlled trials using
ACEI or ARB to treat DR were released from the EUCLID
(EURODIAB Controlled Trial of Lisinopril in Insulin-De-
pendentDiabetes;ACEItreatment)[134]andDIRECT(Dia-
betic Retinopathy Candesartan Trial; ARB treatment) [24,
25]. Afterwards, RASS (Renin-Angiotensin System Study) in
which both inhibitors were tested in DR patients was also
released [26]. Large number of participants were examined
in these trials (354 (type 1 diabetes) for EUCLID, 1421 (type
1) and 1905 (type 2) for DIRECT, and 285 (type 1) for RASS,
resp.), and the results from all three studies provided strong
evidence that RAS inhibition delays the onset or prevents the
development of human DR symptom. However, these treat-
ments were not universally beneﬁcial. For example, in DI-
RECT, ARBs were not eﬀective with respect to primary end-
points and had diﬀering eﬀects regarding secondary end-
points in diﬀerent patient groups (type I or type II diabetes)
[24, 25].
Clues for why RAS inhibition is eﬀective for treating DR
have come from animal studies. Streptozotocin (STZ) injec-
tions in rodents induce leukocyte stasis, blood vessel hyper-
permeability, and formation of acellular capillaries. Impor-
tantly, ERG recordings are attenuated in rodents after STZ
injections before vascular phenotypes are observed, indicat-
ingthatneuronaldysfunctionprecedesneovascularizationin
diabetic models [9, 135]. Apoptosis of retinal neurons is also
observed in later stage [136]. The administration of ACEI
[137–140], ARB [10, 13, 14, 141], or PRRB [142]h a sb e e n
shown to rescue the vascular phenotypes of STZ-induced
diabetic retinas. To generate another and more severe model
of DR, Ren-2 transgenic rats (that have severe hypertension
due to genetic knock-in of a mouse ren-2 renin gene [143])
can be injected with STZ. In these rats advanced vascular
phenotypes are observed (including abnormal endothelial
proliferation). Even in this model ACEI [144]o rA R B[ 19,
145, 146] administration served as eﬀective treatments. RAS
inhibitors probably function by suppressing inﬂammatory
cascades [10, 14] and by preventing oxidative stress [147]
by limiting NFκB and NAD(P)H activation. RAS inhibitors
may also function to directly inhibit glucose accumulation
intoretinalcellsbymodulatingGLUT-1(glucosetransporter
1) expression [148]. Furthermore, ARB was reported to in-
ﬂuencetheexpressionofglyoxalaseI,akeyregulatorofAGEs
[11]. Lastly, even though AT1R and AT2R are considered
to have opposing functions AT2R inhibition may also
eﬀectively treat DR by suppressing VEGF and angiopoietin-2
expression levels in experimental retinopathies [33, 149].
4.4. Age-Related Macular Degeneration (AMD). A M Di so n e
of the leading causes of blindness especially in western coun-
tries. The greatest risk factors are aging and smoking [1],
and the central phenotypes are choroidal neovascularization
(CNV; wet AMD) and atrophy of photoreceptors and RPE
cells (dry AMD). While no cure exists for dry AMD, wet
AMD is currently treated with VEGF inhibitors [112, 113].
Inﬂammation exacerbates the wet AMD phenotype since in-
ﬁltrating macrophages promote CNV formation [150–152].
Experimental CNV can be induced using laser coagulation
to mechanically disrupt Bruch’s membrane. The size of the
laser-induced lesions after treatment with ACEI [153], ARB
[16], and PRRB [154] is signiﬁcantly reduced. Furthermore,
AT1R-deﬁcient mice are resistant to laser-induced CNV
[154].RASinhibitionmayprotectagainstCNVformationby
inhibiting RAS activity and suppressing ERK signaling (di-
rectlywith(pro)reninreceptor-mediatedintracellularsignal-
ing) [154].
RPE cells are positioned between the choroidal vascula-
ture and photoreceptors and have function to maintain the
visual (retinoid) cycle and to form a tight seal that prevents
choroidal vessel invasion. Angiotensin II signaling in RPE
cells increases abnormal production [155–157] and excessive
turnover [158] of ECM via MMP (matrix metalloprotein-
ase)-2 and -14 thereby weakening the seal that prevent chor-
oidal EC invasion. These studies suggest that RAS inhibition
may be an eﬀe c t i v et r e a t m e n tf o rA M Da sw e l la sD R .
4.5. Glaucoma. Glaucoma is another age-related and high
incidence ocular disease [2]. The feature of this disease is
neurodegenerative of RGCs, but it can be caused by hetero-
geneousandcomplexmechanisms.Onedirectmechanismto
induce RGC death is to increase the intraocular pressure
(IOP). Studies devoted to developing new methods of con-
trolling IOP are critical and ongoing. However, a subpopu-
lation of glaucoma patients have normal IOP (normal ten-
sion glaucoma, NTG). This complicates the development of
eﬀectivetherapiessincebothformsareinducedbyseemingly
separatemechanisms.SomeRAScomponentsincludingang-
iotensin II receptors are expressed in CB cells [90, 159, 160]
that secrete aqueous humor and regulate IOP. Like other
antihypertensive drugs such as calcium channel blockers,
ACEI or ARB decreases IOP in humans and other primates
[161–165] although IOP is considered to be regulated inde-
pendently of systemic blood pressure. In an experimental
modelofhighIOPandglaucoma,ARBtreatmentseﬀectively
suppress RGC death [23]. These ﬁndings suggest that RAS
inhibition may be eﬀective for treating glaucoma patients
with high IOP.
5. RASInhibitionProtectsBrainand
RetinalNeurons
Angiotensin II receptors are expressed inside and outside of
the BBB [75, 76, 79–81] and the BRB [8, 92, 99, 100] indicat-
ing that both circulating and tissue RAS exist in the CNS,6 International Journal of Inﬂammation
and if dysregulated, could elicit pathological eﬀects. Indeed,
RAS inhibition can attenuate the degree of inﬂammation in
the brain and the eye [166, 167]. Inhibiting RAS can prevent
experimental brain injuries induced by middle cerebral
artery occlusion [168, 169] by suppressing vascular inﬂam-
mation [170], including BBB breakdown [171], and/or regu-
lating neural apoptosis directly [169]. Interestingly, AT2R is
more highly expressed in developing neuronal tissues in vivo
than in adult tissues [172] and AT2R stimulation promotes
axonal regeneration of optic nerve [173] and minimizes
formation of ischemia-induced cerebral lesions [174]. This
suggeststhatARB,whichnotonlyblocksAT1Rbutalsocaus-
es angiotensin II to bind AT2R [175], may be an ideal drug
for treating inﬂammatory diseases in the CNS. Inhibition
of RAS may also prevent stress-induced behaviors including
anxiety, depression, and panic by suppressing the release
of corticotrophin-releasing factor [176–178]. Furthermore,
recent studies suggest that brain RAS may potentiate Al-
zheimer’s disease progression by stimulating the production
of beta amyloid [179–182].
Retinal dysfunction as detected in ERG recordings can
be observed in early diabetic animal models and in humans
before vascular changes and neural cell loss are observed
[135]. Amazingly, these deﬁcits can be prevented by in-
hibiting RAS [9, 183, 184]. We have reported that ARB pre-
vents retinal dysfunction (e.g., decrease of amplitude and an
extensionoftheimplicittimeofERG)inEIU[8]andinSTZ-
induced early diabetic retinas [9]. Furthermore, in these in-
ﬂamed retinas, we determined that angiotensin II prompted
the degradation of the presynaptic protein synaptophysin
through the ubiquitin proteasome system (UPS) [8, 9]. UPS-
mediated degradation of rhodopsin (part of the light-res-
ponsive complex in photoreceptors) can also be observed in
EIU via STAT3 activation (which operates downstream of
AT1R) [8, 185]. Additionally, STAT3 signaling serves as a
negative regulator of rhodopsin in diﬀerentiating photore-
ceptors during retinal development [186, 187]. Thus, regu-
lating angiotensin-II-induced protein degradation could ser-
veasanimportantneuroprotectivemeasure[188](Figure 3).
Another target of inﬂammation is reactive glia including
microglia, astrocytes, and Muller glia. Activated glia cause
gliosis and alter proper neuronal morphology. Microglia are
resident CNS myeloid-derived cells and mediate critical im-
mune and inﬂammatory responses. AT1R signaling indu-
ces activation of microglia via NFκB and AP-1 [189, 190].
GFAP (glial ﬁbrillary acidic protein) is a diﬀerential and re-
active marker of astrocyte and Muller glia, respectively, and
its transcription is regulated by STAT3 activation [191]. The
activation of astrocytes and Muller glia in experimental re-
tinopathy can be prevented by ARB [8, 192]( Figure 3),
although it is important to consider that the contributions of
reactive glia can be context dependent [193].
IOP-independent RGC apoptosis can be observed in
STZ-induced diabetes [136], after ischemia/reperfusion
[194], after optic nerve crush [195], and after intraocular
NMDA (N-methyl-D-aspartic acid) injections [196] in ani-
malmodels.RGClossindiabetichypertensivemodelscanbe
prevented by ARB which restores oxidative redox and mito-
chondrial functions [22]. ACEI or ARB also prevents RGC
apoptosis in ischemia/reperfusion models by suppressing
toxicoxidativestress[21].ARBcanalsorescuedyingamacri-
ne cells in OIR [20]. Polymorphisms of RAS pathway genes
are reported to be associated with brain infarction or its
earlylesion[197–199]andAT2Rgenepolymorphismsarere-
ported to be associated with the risk of NTG [107]. These
ﬁndings may indicate that RAS inhibitors may directly pro-
tect retinal neurons from apoptosis and further suggest that
RAS inhibition may be useful for therapeutic treatments of
IOP-independent glaucoma.
6. Conclusion
RAS,whichhasbeenclassicallyknownasbloodpressurereg-
ulator, is becoming widely recognized as a proinﬂammatory
mediator. Many age-related ocular diseases may be caused
or exacerbated by chronic inﬂammation. Cells in the eye
are responsive to circulating and tissue RAS and increasing
evidence indicates that RAS inhibition may prevent various
oculardiseasesincluding uveitis, AMD,andglaucoma.Based
on the ﬁndings from multiple clinical trials, RAS inhibitors
are eﬀective therapeutic agents for treating DR although the
results of these studies must be examined critically since the
inhibitors were not universally beneﬁcial. Other groups in-
cluding our own have shown that RAS inhibitors protect
neurons from oxidative stress and apoptosis by preventing
posttranslational ubiquitination of proteins critical for re-
tinal functions. Although not mentioned previously in this
paper, another new and exciting RAS inhibitor, aliskiren (a
direct renin inhibitor), has been developed. It may actually
mediate more robust vascular protection than either ACEI
or ARB [200]. Therefore, work is underway to characterize
existing RAS inhibitors and to develop novel inhibitors since
they hold great promise for attenuating chronic inﬂam-
mation and for treating multiple ocular and nonocular
diseases.
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